Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies

被引:84
作者
Qi, Xingshun [1 ]
Li, Jianjun [2 ]
Deng, Han [1 ]
Li, Hongyu [1 ]
Su, Chunping [3 ]
Guo, Xiaozhong [1 ]
机构
[1] Gen Hosp, Dept Gastroenterol, Shenyang Mil Area, Shenyang 110840, Liaoning, Peoples R China
[2] China Med Univ, Affiliated Hosp 1, Dept Radiotherapy, Shenyang 110001, Liaoning, Peoples R China
[3] Lib Fourth Mil Med Univ, Xian 710032, Shaanxi, Peoples R China
关键词
hepatocellular carcinoma; inflammatory; neutrophil; lymphocyte; prognosis; DONOR LIVER-TRANSPLANTATION; INFLAMMATION-BASED SCORES; ARTERIAL INFUSION CHEMOTHERAPY; RECURRENCE-FREE SURVIVAL; TRANSARTERIAL CHEMOEMBOLIZATION; PREOPERATIVE NEUTROPHIL; PREDICTS SURVIVAL; TUMOR RECURRENCE; HEPATIC RESECTION; BLOOD NEUTROPHIL;
D O I
10.18632/oncotarget.9942
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and aims: Neutrophil to lymphocyte ratio (NLR) is an inflammatory-based marker. A systematic review and meta-analysis was performed to explore the prognostic role of NLR in patients with hepatocellular carcinoma (HCC). Results: Overall, 598 papers were identified, of which 90 papers including 20,475 HCC patients were finally included. Low baseline NLR was significantly associated with better overall survival (HR = 1.80, 95% CI: 1.59-2.04, p < 0.00001) and recurrence-free or disease-free survival (HR = 2.23, 95% CI: 1.80-2.76, p < 0.00001). Low post-treatment NLR was significantly associated with better overall survival (HR = 1.90, 95% CI: 1.22-2.94, p = 0.004). Decreased NLR was significantly associated with overall survival (HR = 2.23, 95% CI: 1.83-2.72, p < 0.00001) and recurrence-free or disease-free survival (HR = 2.23, 95% CI: 1.83-2.72, p < 0.00001). The findings from most of subgroup meta-analyses were consistent with those from the overall meta-analyses. Materials and Methods: All relevant literatures were identified via PubMed, EMBASE, and Cochrane library databases. Hazard ratio (HR) with 95% confidence interval (95% CI) was calculated. Subgroup meta-analyses were performed according to the treatment options, NLR cut-off value ranges, and regions. Conclusions: NLR should be a major prognostic factor for HCC patients. NLR might be further incorporated into the prognostic model of HCC.
引用
收藏
页码:45283 / 45301
页数:19
相关论文
共 108 条
[1]  
Abdelmessih RM, 2011, HEPATOLOGY, V54, p1380A
[2]   NEUTROPHIL LYMPHOCYTE RATIO (NLR) AT DIAGNOSIS IS A PREDICTOR FOR SURVIVAL IN PATIENTS RECEIVING SORAFENIB FOR ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A LARGE UK COHORT [J].
Afshar, M. ;
Clarke, H. ;
Jackson-Wilding, A. ;
Ahmed, A. ;
Ma, Y. T. ;
Punia, P. .
JOURNAL OF HEPATOLOGY, 2015, 62 :S442-S442
[3]   A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Analysis of 865 Consecutive Liver Transplant Recipients [J].
Agopian, Vatche G. ;
Harlander-Locke, Michael ;
Zarrinpar, Ali ;
Kaldas, Fady M. ;
Farmer, Douglas G. ;
Yersiz, Hasan ;
Finn, Richard S. ;
Tong, Myron ;
Hiatt, Jonathan R. ;
Busuttil, Ronald W. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 220 (04) :416-427
[4]   Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis [J].
Aino, Hajime ;
Sumie, Shuji ;
Niizeki, Takashi ;
Kuromatsu, Ryoko ;
Tajiri, Nobuyoshi ;
Nakano, Masahito ;
Satani, Manabu ;
Yamada, Shingo ;
Okamura, Shusuke ;
Shimose, Shigeo ;
Sumie, Hiroaki ;
Torimura, Takuji ;
Sata, Michio .
MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) :393-398
[5]  
[Anonymous], MED ONCOL
[6]  
[Anonymous], 2013, CHIN J CANC PRE TREA
[7]  
[Anonymous], CHINESE J CANC
[8]   Analysis of Factors Affecting Recurrence of Hepatocellular Carcinoma After Liver Transplantation With a Special Focus on Inflammation Markers [J].
Bertuzzo, Valentina Rosa ;
Cescon, Matteo ;
Ravaioli, Matteo ;
Grazi, Gian Luca ;
Ercolani, Giorgio ;
Del Gaudio, Massimo ;
Cucchetti, Alessandro ;
D'Errico-Grigioni, Antonietta ;
Golfieri, Rita ;
Pinna, Antonio Daniele .
TRANSPLANTATION, 2011, 91 (11) :1279-1285
[9]  
Bodzin A, 2015, AM J TRANSPLANT, V15, P89
[10]  
Bronson N, 2012, HPB, V14, P456